3-bromo-2-chlorophenyl acetate | 1111084-93-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 3-bromo-2-chlorophenyl acetate
• 英文别名: (3-bromo-2-chlorophenyl) acetate
• CAS: 1111084-93-5
• 化学式: C₈H₆BrClO₂
• 分子量: 249.491
• InChiKey: BPNAIQVHJRJPGW-UHFFFAOYSA-N

物化性质

• 沸点：
  296.3±30.0 °C(Predicted)
• 密度：
  1.607±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-bromo-2-chlorophenyl acetate 在 aluminum (III) chloride 作用下， 反应 2.0h， 以64%的产率得到4-bromo-3-chloro-2-hydroxyacetophenone
  参考文献：
  名称：

  Structural Evolutions of Salicylaldoximes as Selective Agonists for Estrogen Receptor β

  摘要：

  The bioisosteric replacement of the phenol ring, a signature functional group of most estrogen receptor (ER) ligands, with a hydrogen-bonded pseudocyclic ring, led to the development of a novel class of nonsteroidal ER-ligands based on a salicylaldoxime template. A series of structural modifications were applied to selected molecules belonging to the monoaryl-salicylaldoxime chemical class in an attempt to improve further their ER beta-selective receptor affinity and agonist properties. Among several modifications, the best results were obtained by the simultaneous introduction of a meta-fluorine atom into the para-hydroxyphenyl substituent present in the 4-position of salicylaldoxime, together with the insertion of a chloro group in the 3-position of the central scaffold. The resulting compound showed the best affinity (K-i = 7.1 nM) and selectivity for ER beta over ER alpha. Moreover, in transcription assays, it proved to be a selective and potent ER beta-full agonist with an EC50 of 4.8 nM.

  DOI：

  10.1021/jm801458t
• 作为产物：
  描述：

  3-氯-2-甲基苯酚 、 乙酰氯 在 四丁基硫酸氢铵 、 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.5h， 以79%的产率得到3-bromo-2-chlorophenyl acetate
  参考文献：
  名称：

  Structural Evolutions of Salicylaldoximes as Selective Agonists for Estrogen Receptor β

  摘要：

  The bioisosteric replacement of the phenol ring, a signature functional group of most estrogen receptor (ER) ligands, with a hydrogen-bonded pseudocyclic ring, led to the development of a novel class of nonsteroidal ER-ligands based on a salicylaldoxime template. A series of structural modifications were applied to selected molecules belonging to the monoaryl-salicylaldoxime chemical class in an attempt to improve further their ER beta-selective receptor affinity and agonist properties. Among several modifications, the best results were obtained by the simultaneous introduction of a meta-fluorine atom into the para-hydroxyphenyl substituent present in the 4-position of salicylaldoxime, together with the insertion of a chloro group in the 3-position of the central scaffold. The resulting compound showed the best affinity (K-i = 7.1 nM) and selectivity for ER beta over ER alpha. Moreover, in transcription assays, it proved to be a selective and potent ER beta-full agonist with an EC50 of 4.8 nM.

  DOI：

  10.1021/jm801458t

文献信息

• Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
  申请人：ZHEJIANG UNIVERSITY

  公开号：US10233180B2

  公开（公告）日：2019-03-19

  Disclosed are new substituted nitrogen-containing heterocyclic derivatives represented by formula (I) as AKT inhibitors, optical isomers, pharmaceutically acceptable salts or solvates thereof, wherein the definition of R1, R2, R3, R4, R5, R6, ring A, ring C, B, Q, Y, Z and m is shown in the description for details. In addition, medicaments comprising the derivatives as active components are also disclosed, which can be useful for treating proliferative diseases, such as cancer and inflammation, especially diseases relating to AKT kinase.

  本发明公开了式(I)代表的作为AKT抑制剂的新取代含氮杂环衍生物、其光学异构体、药学上可接受的盐或溶液，其中R1、R2、R3、R4、R5、R6、环A、环C、B、Q、Y、Z和m的定义详见说明。此外，还公开了包含这些衍生物作为活性成分的药物，可用于治疗增殖性疾病，如癌症和炎症，尤其是与 AKT 激酶有关的疾病。
• SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OF ANTITUMOR THEREOF
  申请人：Zhejiang University

  公开号：EP3124486B1

  公开（公告）日：2020-12-09
• FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3860984A1

  公开（公告）日：2021-08-11
• SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OFANTITUMOR THEREOF
  申请人：ZHEJIANG UNIVERSITY

  公开号：US20170107213A1

  公开（公告）日：2017-04-20

  Disclosed are new substituted nitrogen-containing heterocyclic derivatives represented by formula (I) as AKT inhibitors, optical isomers, pharmaceutically acceptable salts or solvates thereof, wherein the definition of R1, R2, R3, R4, R5, R6, ring A, ring C, B, Q, Y, Z and m is shown in the description for details. In addition, medicaments comprising the derivatives as active components are also disclosed, which can be useful for treating proliferative diseases, such as cancer and inflammation, especially diseases relating to AKT kinase.
• [EN] FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE<br/>[FR] DÉRIVÉS DE FLAVONE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE MALADIE DU VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020070088A1

  公开（公告）日：2020-04-09

  The present invention provides novel compounds having the general formula (Formula I) : wherein R1 to R6, G1, G2, A1 to A4 and m are as described herein, compositions including the compounds and methods of using the compounds.